Company news

Oric Pharmaceuticals, Inc. news in 2025

Oric Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 4, 2025

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 4, 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

December 3, 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

December 2, 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

November 30, 2025

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 23, 2025

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

November 12, 2025

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

November 12, 2025

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

November 5, 2025

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

October 26, 2025

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

August 17, 2025

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

August 11, 2025

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 27, 2025

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 26, 2025

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

May 4, 2025

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 24, 2025

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

February 24, 2025

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

February 17, 2025

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

January 12, 2025

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

January 12, 2025

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 2, 2025

Decks in 2025